دورية أكاديمية
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab
| العنوان: | Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab |
|---|---|
| المؤلفون: | Nardone V., Tini P., Pastina P., Botta C., Reginelli A., Carbone S. F., Giannicola R., Calabrese G., Tebala C., Guida C., Giudice A., Barbieri V., Tassone P., Tagliaferri P., Cappabianca S., Capasso R., Luce A., Caraglia M., Mazzei M. A., Pirtoli L., Correale P. |
| المساهمون: | Nardone V., Tini P., Pastina P., Botta C., Reginelli A., Carbone S.F., Giannicola R., Calabrese G., Tebala C., Guida C., Giudice A., Barbieri V., Tassone P., Tagliaferri P., Cappabianca S., Capasso R., Luce A., Caraglia M., Mazzei M.A., Pirtoli L., Correale P. |
| بيانات النشر: | Spandidos Publications |
| سنة النشر: | 2020 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | Immunology, Nivolumab, Non-small cell lung cancer, Programmed cell death protein 1, Radiomic, Survival, Texture analysis |
| الوصف: | Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolongs survival in a number of patients, this treatment is hampered by high cost. Therefore, the identification of predictive markers of response to treatment in patients is required. In this context, PD-1/PDL1 blockade antitumor effects occur through the reactivation of a pre-existing immune response, and the efficacy of these effects is strictly associated with the presence of necrosis, hypoxia and inflammation at the tumour sites. It has been indicated that these events can be evaluated by specific assessments using a computed tomography (CT) texture analysis (TA) or radiomics. Therefore, a retrospective study was performed, which aimed to evaluate the potential use of this analysis in the identification of patients with NSCLC who may benefit from Nivolumab treatment. A retrospective analysis was performed of 59 patients with metastatic NSCLC who received Nivolumab treatment between January 2015 and July 2017 at Siena University Hospital (35 patients, training dataset), Catanzaro University Hospital and Reggio Calabria Grand Metropolitan Hospital, Italy (24 patients, validation dataset). Pre- and post-contrast CT sequences were used to contour the gross tumour volume (GTV) of the target lesions prior to Nivolumab treatment. The impact of variations on contouring was analysed using two delineations, which were performed on each patient, and the TA parameters were tested for reliability using the Intraclass Coefficient Correlation method (ICC). All analyses for the current study were performed using LifeX Software©. Imaging, clinical and pathological parameters were correlated with progression free survival and overall survival (OS) using Kaplan Meier analysis. An external validation testing was performed for the TA ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31966081; info:eu-repo/semantics/altIdentifier/wos/WOS:000508895000055; volume:19; issue:2; firstpage:1559; lastpage:1566; numberofpages:8; journal:ONCOLOGY LETTERS; http://hdl.handle.net/10447/513588Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85077918734 |
| DOI: | 10.3892/ol.2019.11220 |
| الإتاحة: | https://doi.org/10.3892/ol.2019.11220Test http://hdl.handle.net/10447/513588Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.63891DF6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3892/ol.2019.11220 |
|---|